Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer

BACKGROUND: In the PAOLA-1 trial, olaparib plus bevacizumab demonstrated significant clinical benefit following partial or complete response to platinum-based chemotherapy in homologous recombination deficiency (HRD)-positive ovarian cancer. Our study evaluated the cost effectiveness of olaparib plu...

Descripción completa

Detalles Bibliográficos
Autores principales: Elsea, David, Fan, Lin, Mihai, Adela, Moustaid, Fadoua El, Simmons, Daniel, Monberg, Matthew, Muston, Dominic
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596645/
https://www.ncbi.nlm.nih.gov/pubmed/36036344
http://dx.doi.org/10.1007/s41669-022-00338-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596645/
https://www.ncbi.nlm.nih.gov/pubmed/36036344
http://dx.doi.org/10.1007/s41669-022-00338-2

Ejemplares similares